Navigation Links
Amgen To Host Post American Society of Hematology (ASH) Summary Webcast
Date:12/10/2013

THOUSAND OAKS, Calif., Dec. 10, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will hold a post American Society of Hematology (ASH) summary webcast on Wednesday, Dec. 11, 2013, at 11 a.m. PST. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc. and Anthony C. Hooper, executive vice president of Global Commercial Operations at  Amgen, will participate in the call to discuss a brief summary of data presented at ASH. In addition, they will discuss a summary of feedback received from key opinion leaders and the steps Amgen is taking to develop Kyprolis® (carfilzomib) across all lines of therapy to address unmet needs in multiple myeloma patients.

Live audio of the investor call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... USA (PRWEB) November 26, 2014 Biomedical ... accuracy, additive systems to enable 3D manufacture at the ... road conditions are among finalists in nine categories for ... The awards are sponsored by SPIE, the international ... Media . , Winners will be announced by industry ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is a professional and in-depth research report on ... information, like its definition, classification, application, and industry ... report covers the international market analysis, including China’s ... the US, Europe, Asia, China, Japan etc. regions) ...
(Date:11/26/2014)... YORK , Nov. 26, 2014 The ... may indicate the company is looking to expand in ... further sales.  The healthcare market research firm says that  ... to Kalorama Information,s biennial survey of the IVD market ... and any change in its composition would likely affect ...
(Date:11/26/2014)... November 26, 2014 On January, 14, ... Baltimore and Washington D.C. science community to the UMBC ... event, sponsored by the Protein Society, will take place ... Center, Room 312. Through discussion, presentations and workshops, ... importance of proteins, their role in the industry and ...
Breaking Biology Technology:Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... Renowned Clinicians in the Fields of Cancer and Women,s Health ... to Best ... Address Current Medical Needs, REHOVOT, Israel and ... ROSG) announced,today the establishment of its Medical Advisory Board. Rosetta ...
... Pa., Feb. 4 Centocor, Inc. announced today,that ... 1275),has been accepted for review by the U.S. ... adult patients with chronic moderate to severe plaque,psoriasis. ... a novel,mechanism of action that targets the cytokines ...
... Aricept Prescription Rates, According to a New Report from Decision ... ... Feb. 4 Decision Resources, one of the,world,s leading research and ... owns a dominating,42.4% patient share for first-line treatment of newly diagnosed ...
Cached Biology Technology:Rosetta Genomics Establishes Medical Advisory Board 2Rosetta Genomics Establishes Medical Advisory Board 3Rosetta Genomics Establishes Medical Advisory Board 4Rosetta Genomics Establishes Medical Advisory Board 5Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 3Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease 2Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease 3
(Date:11/21/2014)... REDMOND, Wash. , Nov. 20, 2014 ... access for the Internet of Things (IoT), today announced ... position of chief operating officer. Previously a strategic advisor ... marketing, finance, and operations. Mr. Traynor is based out ... . He reports to Chris Muench , ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/7/2014)... Researchers led by Dr. Debra Auguste, associate professor, ... at The City College of New York, have ... treatment for one of the most aggressive forms ... (TNBCs) have a high mortality rate owing to ... effective therapeutic options. However, Professor Auguste,s team, discovered ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... The March of Dimes has extended its Prematurity Campaign ... address preterm birth globally. The expansion, announced at the ... the national action plan being created during the two-day ... birth. "The March of Dimes Prematurity Campaign has ...
... shot of youthful vigor in a stem cell experiment by ... for research on new treatments for age-related degenerative conditions such ... a new study to be published June 15 in an ... identified two key regulatory pathways that control how well adult ...
... has received $400,000 from the National Oceanic and Atmospheric ... system for the Mid-Atlantic region, spanning the waters from ... to the continental shelf. Nearly 25 percent of the ... initiative is part of the national Integrated Ocean Observing ...
Cached Biology News:March of Dimes announces Prematurity Campaign expansion at Surgeon General's conference 2March of Dimes announces Prematurity Campaign expansion at Surgeon General's conference 3Stem cell researchers give old muscle new pep 2Stem cell researchers give old muscle new pep 3Stem cell researchers give old muscle new pep 4UD nets NOAA funding for Mid-Atlantic ocean observing 2
... LAS-3000 imaging system combines new CCD ... interface, providing significantly improved system sensitivity ... The system is especially dedicated to ... system for Western blotting applications.,Fuiji's LAS-3000 ...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... The Fujifilm Life Science LAS-3000mini ... especially dedicated to chemiluminescence applications, and ... blotting applications., Fuiji 's LAS-3000 provides ... and digitization. , Glowell calibration standards ...
... FLIM system combines the space and time dimensions ... of the optical microscope to open new horizons ... light source for excitation, the decay of a ... of the decay measured. Subtle changes in ...
Biology Products: